Sanofi Consumer Healthcare India Limited reported a 12% year-on-year increase in revenue to Rs 263.1 crore for the third quarter of 2026, powered by a strong 19% jump in domestic sales.

 

The company’s Profit Before Tax (PBT) rose 22% year-on-year to Rs 102.7 crore, while earnings per share (EPS) increased 22%, or Rs 5.95, supported by higher revenue and improved profitability.

 

The company’s performance also reflected continued momentum over the nine months ended 2026, with revenue from operations climbing 16% year-on-year to Rs 728 crore. 

 

Domestic sales grew 15% during the nine-month period, aided by a relaunch, while export sales advanced 19%. PBT for the period increased 24% year-on-year, underscoring the company’s continued focus on profitable growth.

 

Commenting on the results, Himanshu Bakshi, Managing Director, Sanofi Consumer Healthcare India Limited, “Our Q3 performance reflects the disciplined execution of our strategy and the strength of our portfolio. We delivered healthy growth, driven by volume expansion and market share gains across key brands. Our investments in brand building and expanding our distribution footprint and Healthcare Professional reach are enabling us to serve more consumers.”

 

The results highlight the company’s growth momentum, led by stronger domestic demand, gains across key brands and continued expansion in its distribution network.